PRAMEF6 CRISPR/Cas9 KO Plasmid (h): sc-417298
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- PRAMEF6 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the PRAMEF6 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PRAMEF6 CRISPR/Cas9 KO Plasmid (h) | sc-417298 | 20 µg | $397.00 |
Overview
PRAMEF6 (preferentially expressed antigen in melanoma family member 6) is a primate-specific PRAME family protein with highly restricted expression in normal tissues and frequent derepression in cancers, consistent with cancer/testis antigen biology. Although PRAMEF6 remains less functionally characterized than PRAME, PRAME-family proteins are implicated in transcriptional and epigenetic regulation and have been associated with modulation of retinoic acid receptor signaling and cellular differentiation programs. Altered expression of PRAME-family genes is linked to tumor cell proliferation, immune recognition, and lineage identity, making PRAMEF6 a useful marker and mechanistic target for studying oncogenic transcriptional states. Research applications include profiling PRAMEF6-dependent gene expression networks and interrogating regulatory mechanisms that enable its aberrant activation in malignant contexts.
PRAMEF6 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the PRAMEF6 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the PRAMEF6 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the PRAMEF6 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish PRAMEF6 protein expression.
This CRISPR knockout system enables efficient generation of PRAMEF6-deficient cell models for investigation of PRAMEF6 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting PRAMEF6 exon(s) critical for PRAMEF6 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple PRAMEF6 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by PRAMEF6 CRISPR/Cas9 KO Plasmid (h) and PRAMEF6 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the PRAMEF6 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by PRAMEF6 HDR Plasmid (h) and PRAMEF6 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by PRAMEF6 homology arms to support homology-directed repair at defined PRAMEF6 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.